AI assistant
Granules India Ltd. Earnings Release 2026
60224_rns_2026-04-29_86e10c23-6388-4796-88ce-fde93211d8a5.pdf
Earnings Release
Open in viewerOpens in your device viewer
GRANULES
Date: April 29, 2026
To,
National Stock Exchange of India Limited
BSE Limited
Symbol: NSE: GRANULES: BSE: 532482
Dear Sir,
Sub: Press Release to the Analysts/Investors
We refer to the audited financial results for the fourth quarter and financial year ended on March 31, 2026, submitted to you today i.e., on April 29, 2026. We are now enclosing the press release to the Analysts/Investors.
This is pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Kindly take the above information on record.
For GRANULES INDIA LIMITED
CHAITANYA TUMMALA
Digitally signed by
CHAITANYA TUMMALA
Date: 2026.04.29 13:00:49
+05'30'
CHAITANYA TUMMALA
(COMPANY SECRETARY & COMPLIANCE OFFICER)
REGISTERED OFFICE
Granules India Limited
CIN: L24110TG1991PLC012471
15th Floor, Granules Tower, Botanical Garden Road, Kondapur, Hyderabad – 500084, Telangana, India
Contact Us: Tel: +91 40 69043500 | Fax: +91-40-23115145 | [email protected]
www.granulesindia.com
GRANULES
Press Release
for Immediate Release
Q4FY26 Revenue from operations at INR 14,706 Mn up 23% YoY, EBITDA at INR 3,521 Mn up 40% YoY, PBT before Exceptional Item at INR 2,464 Mn up 48% YoY, PAT at INR 2,016 Mn up 33% YoY.
Hyderabad, India, April 29, 2026: Granules India Ltd., a vertically integrated pharmaceutical company, today announced its financial results for the quarter and financial year ended March 31, 2026.
Financial Summary (All numbers in INR Mn)
| QUARTERLY CONSOLIDATED FINANCIALS | Q4FY26 | Q3FY26 | Growth (QoQ) | Q4FY25 | Growth (YoY) |
|---|---|---|---|---|---|
| Revenue from Operations | 14,706 | 13,879 | 6% | 11,974 | 23% |
| EBITDA | 3,521 | 3,081 | 14% | 2,524 | 40% |
| EBITDA % | 24% | 22% | 21% | ||
| PBT Before Exceptional Item | 2,464 | 2,022 | 22% | 1,668 | 48% |
| Exceptional Item / (Income) | (159) | (308) | |||
| PAT | 2,016 | 1,502 | 34% | 1,520 | 33% |
| PAT % | 14% | 11% | 13% | ||
| ANNUAL CONSOLIDATED FINANCIALS | FY26 | FY25 | Growth (YoY) | ||
| --- | --- | --- | --- | ||
| Revenue from Operations | 53,656 | 44,816 | 20% | ||
| EBITDA | 11,851 | 9,452 | 25% | ||
| EBITDA % | 22% | 21% | |||
| PBT Before Exceptional Item | 7,950 | 6,294 | 26% | ||
| Exceptional Item / (Income) | 100 | (308) | |||
| PAT | 5,950 | 5,015 | 19% | ||
| Net Profit Margin | 11% | 11% |
Financial and Business Summary for Q4FY26
- Revenue from Operations of Q4FY26 stood at INR 14,706 Mn, a growth of 23% YoY, Revenue share from the North America is 72% in Q4 FY26 as compared to 79% in Q4 FY25 and from the Europe is 17% in Q4FY26 as compared to 8% in Q4FY25.
- Finished dosages (FD), Active Pharmaceuticals Ingredients (API), Pharmaceutical Formulation Intermediates (PFI), and Peptide/CDMO contribute 73%, 13%, 9% and 5% of revenue from operations respectively for Q4FY26.
- ROCE improved to 17.6% in FY26 from 16.6% in FY25.
- Net debt stood at INR 4,021 Mn, a reduction of INR 3,040 Mn from Q4FY25 and Net debt to EBITDA at 0.34x
Commenting on the results, Dr. Krishna Prasad Chigurupati, Chairman & Managing Director of Granules India Limited said, "We delivered a strong performance in Q4FY26, driven by continued portfolio expansion, disciplined execution, and steady progress across regulatory, compliance, and sustainability initiatives. The quarter reflects improving earnings quality and sustained advancement in Complex Generics and the Peptides CDMO platform".
About Granules India Ltd. (BSE: 532482, NSE: GRANULES)
Granules India Limited, incorporated in 1991 is a vertically integrated fast growing Indian pharmaceutical company headquartered at Hyderabad with best-in-class facilities and commitment to operational excellence, quality, and customer service. We are among the few pharmaceutical companies in the world to be present in the manufacturing of entire value chain – from Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs), Finished Dosages (FDs) and Peptides CDMO. Our products are being distributed to over 300+ customers in regulated and semi-regulated markets with a global presence extending to over 80+ countries with offices across India, US, and UK. The Company has 10 manufacturing facilities out of which 7 are in India, 2 in the USA and 1 in Switzerland and has regulatory approvals from US FDA, EDQM, EU GMP, COFEPRIS, WHO GMP, TGA, K FDA, DEA, MCC, and HALAL.
Safe Harbor
This document includes certain forward-looking statements. These statements are based on management's current expectations or beliefs and are subject to uncertainty and changes in circumstances. Actual results may vary materially from those expressed or implied by the statements herein due to changes in economic, business, competitive, technological, and/or regulatory factors. Granules India Ltd., its directors, and any of the affiliates or employees are under no obligation to and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events, or otherwise.
| Contacts: | |
|---|---|
| Granules IR Desk | |
| [email protected] | Chaitanya Tummala |
| Company Secretary | |
| [email protected] |